AI
Sunday, August 10, 2025 8:12:29 PM
J-To,
Fact ✅️: LP is a shareholder. And Advent also owns shares of NWBO 😶
You can bet that the smart Harvard lawyer has plans for her NWBO shares and cares about their value. Advent also wants their NWBO shares to grow in value…
LP is wise to focus on a key factor:
Manufacturing is one of the greatest challenges in developing & commercializing innovative cell-based products. NWBO seems to have strategically lined up MULTIPLE potential manufacturing options for both clinical trials & commercialization. We are looking forward to further announcements about manufacturing developments!
Who do you think deserves the credit for orchestrating NWBO’s collaboration with both Pittsburgh & Roswell?
Thanks to LP, Dr. Liau joined the SAB at NWBO, and now we have really exciting developments with Dr. Kalinski too: He is well-connected with Roswell and has now returned to Pittsburgh where he has access to Pitt’s Tumor Microenvironment Center and the soon-to-open Pitt BioForge!
On April 30th, Dr. Kalinski gave a presentation entitled Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants and DC-assisted T Cell Therapies…
Next month, at the Annual Marie Sklodowska-Curie Symposium on Cancer Research & Care, Dr. Kalinski will give a brief version of the same highly relevant presentation entitled Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants & T Cell Therapies with DC-sensitized T Cells
LP has been laying the groundwork & building prospective value for the NWBO shares that she owns. For example, NWBO acquired Flaskworks and now owns a patent-fortified novel manufacturing technology called EDEN that may add a vast amount of additional value to the company.
Beyond UCLA, NWBO also acquired commercial IP licenses from TWO additional renowned research institutions which are both increasingly investing in built-in manufacturing capabilities to streamline & support the clinical development of cell-based therapies (this wasn’t the case during the early development of DCVax). Roswell Park’s newly opened manufacturing facility, and the University of Pittsburgh’s BioForge (currently under construction) are state-of-the-art biomanufacturing centers.
$100 Million to Fund Pitt BioForge
Pitt BioForge
Roswell GMP Engineering & Cell Manufacturing
Fact ✅️: LP is a shareholder. And Advent also owns shares of NWBO 😶
You can bet that the smart Harvard lawyer has plans for her NWBO shares and cares about their value. Advent also wants their NWBO shares to grow in value…
LP is wise to focus on a key factor:
Manufacturing is one of the greatest challenges in developing & commercializing innovative cell-based products. NWBO seems to have strategically lined up MULTIPLE potential manufacturing options for both clinical trials & commercialization. We are looking forward to further announcements about manufacturing developments!
Who do you think deserves the credit for orchestrating NWBO’s collaboration with both Pittsburgh & Roswell?
Thanks to LP, Dr. Liau joined the SAB at NWBO, and now we have really exciting developments with Dr. Kalinski too: He is well-connected with Roswell and has now returned to Pittsburgh where he has access to Pitt’s Tumor Microenvironment Center and the soon-to-open Pitt BioForge!
On April 30th, Dr. Kalinski gave a presentation entitled Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants and DC-assisted T Cell Therapies…
Next month, at the Annual Marie Sklodowska-Curie Symposium on Cancer Research & Care, Dr. Kalinski will give a brief version of the same highly relevant presentation entitled Dendritic Cells in Cancer Immunotherapy: Vaccines, Live Adjuvants & T Cell Therapies with DC-sensitized T Cells
LP has been laying the groundwork & building prospective value for the NWBO shares that she owns. For example, NWBO acquired Flaskworks and now owns a patent-fortified novel manufacturing technology called EDEN that may add a vast amount of additional value to the company.
Beyond UCLA, NWBO also acquired commercial IP licenses from TWO additional renowned research institutions which are both increasingly investing in built-in manufacturing capabilities to streamline & support the clinical development of cell-based therapies (this wasn’t the case during the early development of DCVax). Roswell Park’s newly opened manufacturing facility, and the University of Pittsburgh’s BioForge (currently under construction) are state-of-the-art biomanufacturing centers.
$100 Million to Fund Pitt BioForge
Pitt BioForge
Roswell GMP Engineering & Cell Manufacturing
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
